These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19698584)

  • 21. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
    Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
    J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers.
    Melichar JK; Haida A; Rhodes C; Reynolds AH; Nutt DJ; Malizia AL
    J Psychopharmacol; 2001 Mar; 15(1):9-12. PubMed ID: 11277612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine: more dangerous than most "selective" serotonergic antidepressants.
    Prescrire Int; 2016 Apr; 25(170):96-9. PubMed ID: 27186622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of mirtazapine: a review.
    Montgomery SA
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():37-45. PubMed ID: 8930008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.
    Thase ME
    J Clin Psychiatry; 1998 Oct; 59(10):502-8. PubMed ID: 9818630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
    Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
    J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical measures of rapid onset of action.
    Montgomery SA
    Eur Psychiatry; 1997; 12 Suppl 4():295s-300s. PubMed ID: 19698583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development.
    Montgomery S
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():5-11. PubMed ID: 24921676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.
    Li X; Zhu L; Su Y; Fang S
    PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
    Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
    Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the long-term treatment of major depressive disorder.
    Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
    J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
    Shrivastava RK; Cohn C; Crowder J; Davidson J; Dunner D; Feighner J; Kiev A; Patrick R
    J Clin Psychopharmacol; 1994 Oct; 14(5):322-9. PubMed ID: 7806687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venlafaxine. A review of its pharmacology and therapeutic potential in depression.
    Holliday SM; Benfield P
    Drugs; 1995 Feb; 49(2):280-94. PubMed ID: 7729333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of high-dose venlafaxine in depressed patients.
    Harrison CL; Ferrier N; Young AH
    J Psychopharmacol; 2004 Jun; 18(2):200-4. PubMed ID: 15260908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
    Keks NA; Hope J; Keogh S; Copolov DL
    Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid onset of action of venlafaxine.
    Montgomery SA
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():21-7. PubMed ID: 7622814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.